Abbott, Johnson & Johnson locked in tussle with govt over stent price cap

Boston Scientific said it was engaging with the government and would abide by regulations

A group of global medical technology companies plans to tell Indian officials next month that any further price control measures would risk future investments and make them less likely to introduce new products in the country, according to an industry source familiar with the matter.

The lobbying effort by Abbott Laboratories, Boston Scientific, Johnson & Johnson and others comes after the Prime Minister Narendra Modi-led government in February set a price cap for stents - small wire-mesh structures used to treat blocked arteries - slashing prices that patients pay for some devices by about 75 per cent.

That has sparked a growing